OS Therapies (OSTX) Competitors $1.70 -0.19 (-10.05%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.77 +0.07 (+4.12%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends OSTX vs. SCPH, GLSI, ALEC, MGNX, LYEL, IPHA, VXRT, CRGX, GNLX, and CKPTShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include scPharmaceuticals (SCPH), Greenwich LifeSciences (GLSI), Alector (ALEC), MacroGenics (MGNX), Lyell Immunopharma (LYEL), Innate Pharma (IPHA), Vaxart (VXRT), CARGO Therapeutics (CRGX), Genelux (GNLX), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. scPharmaceuticals Greenwich LifeSciences Alector MacroGenics Lyell Immunopharma Innate Pharma Vaxart CARGO Therapeutics Genelux Checkpoint Therapeutics OS Therapies (NYSE:OSTX) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals & insiders hold more shares of OSTX or SCPH? 89.5% of scPharmaceuticals shares are held by institutional investors. 5.5% of scPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is OSTX or SCPH more profitable? OS Therapies has a net margin of 0.00% compared to scPharmaceuticals' net margin of -264.60%. OS Therapies' return on equity of 0.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% scPharmaceuticals -264.60%-244.93%-68.56% Does the media favor OSTX or SCPH? In the previous week, OS Therapies had 4 more articles in the media than scPharmaceuticals. MarketBeat recorded 5 mentions for OS Therapies and 1 mentions for scPharmaceuticals. scPharmaceuticals' average media sentiment score of 1.54 beat OS Therapies' score of 0.11 indicating that scPharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral scPharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has stronger valuation & earnings, OSTX or SCPH? OS Therapies has higher earnings, but lower revenue than scPharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79MN/AN/AscPharmaceuticals$13.59M11.97-$54.81M-$1.90-1.71 Does the MarketBeat Community believe in OSTX or SCPH? scPharmaceuticals received 153 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 66.67% of users gave scPharmaceuticals an outperform vote. CompanyUnderperformOutperformOS TherapiesOutperform Votes7100.00% Underperform VotesNo VotesscPharmaceuticalsOutperform Votes16066.67% Underperform Votes8033.33% Do analysts recommend OSTX or SCPH? OS Therapies presently has a consensus price target of $17.50, indicating a potential upside of 929.41%. scPharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 361.54%. Given OS Therapies' stronger consensus rating and higher probable upside, equities research analysts clearly believe OS Therapies is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOS Therapies beats scPharmaceuticals on 8 of the 14 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$37.28M$7.04B$5.77B$20.08BDividend YieldN/A2.87%4.78%3.65%P/E RatioN/A5.7325.8234.36Price / SalesN/A312.55453.6615.65Price / CashN/A67.8344.0520.85Price / BookN/A6.747.634.92Net Income-$7.79M$138.11M$3.18B$1.02B7 Day Performance-23.77%-2.54%-1.95%-1.05%1 Month Performance-43.89%-2.00%-0.23%-1.09%1 Year PerformanceN/A-5.04%16.69%13.70% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.4659 of 5 stars$1.70-10.1%$17.50+929.4%N/A$37.28MN/A0.00N/AAnalyst ForecastInsider TradeNews CoverageGap UpSCPHscPharmaceuticals4.2503 of 5 stars$3.36+3.2%$15.00+347.1%-41.8%$167.88M$30.28M-1.7730GLSIGreenwich LifeSciences2.09 of 5 stars$12.56+1.3%$38.00+202.7%-9.2%$165.10MN/A-15.693Positive NewsALECAlector4.0711 of 5 stars$1.68-4.3%$3.75+123.9%-69.9%$164.03M$97.06M-0.99270MGNXMacroGenics3.573 of 5 stars$2.56-1.7%$7.63+198.4%-83.8%$160.35M$58.75M-1.62430News CoverageLYELLyell Immunopharma2.1959 of 5 stars$0.55-4.5%$1.00+82.5%-69.3%$160.10M$130,000.00-0.69270Upcoming EarningsGap UpIPHAInnate Pharma3.0219 of 5 stars$1.90-0.3%$11.50+506.9%-7.8%$158.86M$66.71M0.00220News CoverageGap UpVXRTVaxart1.5356 of 5 stars$0.69-2.4%$4.00+477.2%-49.4%$158.10M$7.38M-1.70120CRGXCARGO Therapeutics3.0941 of 5 stars$3.38-5.7%$15.00+344.4%-82.7%$155.58MN/A-0.79116Gap UpGNLXGenelux1.1851 of 5 stars$4.48+4.7%$18.25+307.4%-34.7%$155.57M$170,000.00-4.7410CKPTCheckpoint Therapeutics3.1849 of 5 stars$3.19-3.2%$12.00+276.8%+63.0%$155.52M$100,000.00-1.7310Gap Down Related Companies and Tools Related Companies scPharmaceuticals Competitors Greenwich LifeSciences Competitors Alector Competitors MacroGenics Competitors Lyell Immunopharma Competitors Innate Pharma Competitors Vaxart Competitors CARGO Therapeutics Competitors Genelux Competitors Checkpoint Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:OSTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OSTX Stock Alerts